A Multi-center, Non-randomized, Non Blinded, Non-controlled Study to Investigate the Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease Associated Pulmonary Hypertension.

Trial Profile

A Multi-center, Non-randomized, Non Blinded, Non-controlled Study to Investigate the Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease Associated Pulmonary Hypertension.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Interstitial lung diseases; Pulmonary hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 29 May 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2018 as reported by ClinicalTrials.gov record.
    • 29 May 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2018 as reported by ClinicalTrials.gov record.
    • 14 Dec 2013 Planned number of patients 20 added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top